Answers are grounded in this paper and cite their sources.
Anal canal squamous cell carcinoma (SCC) is an uncommon malignancy treated primarily with definitive chemoradiotherapy (CCRT). However, treatment responses and long-term outcomes remain heterogeneous. We retrospectively analysed six patients with non-metastatic anal canal SCC treated with definitive CCRT between 2019 and 2024 at a tertiary oncology centre. Clinical presentation, treatment techniques, toxicities, response patterns, salvage interventions, and survival outcomes were evaluated. Stages ranged from IIA to IIIC. Radiotherapy techniques included 3DCRT, IMRT, and VMAT with concurrent mitomycin-based chemotherapy. Four patients achieved durable disease control, including one after salvage pelvic exenteration. Two patients developed persistent or recurrent disease and subsequently died. Acute toxicities were manageable, with only one Grade 3 dermatitis event . Anal canal SCC demonstrates variable clinical behaviour despite standardized CCRT. Careful response assessment, individualized surveillance, and timely salvage treatment remain crucial for optimizing outcomes .
No takes yet. Share an insight, caveat, or question.
Nanda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: